Prescient Therapeutics

Prescient Therapeutics EBITDA per Employee

The EBITDA per Employee of Prescient Therapeutics (PTX.AX) as of Nov 22, 2026 is -3.53 M AUD. In the previous year, EBITDA per Employee was -2.51 M AUD — a change of 40.54% (lower).

EBITDA per Employee

-3.53 MAUD

YoY

40.54%

Last updated:

EBITDA per Employee of Prescient Therapeutics is 2026 -3.53 M AUD. EBITDA per Employee of Prescient Therapeutics was 2025 -2.51 M AUD. It decreases by 40.54% lower compared to the previous year.

The Prescient Therapeutics EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
-1.26 M AUD
Jan 1, 2020
-1.50 M AUD
Jan 1, 2021
-1.81 M AUD
Jan 1, 2022
-2.37 M AUD
Jan 1, 2023
-3.30 M AUD
Jan 1, 2024
-2.40 M AUD
Jan 1, 2025
-2.51 M AUD
Jan 1, 2026
-3.53 M AUD
The Prescient Therapeutics EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-3.53 MAUD+40.54%
-2.51 MAUD+4.87%
-2.40 MAUD-27.31%
-3.30 MAUD+39.26%
-2.37 MAUD+30.81%
-1.81 MAUD+20.76%
-1.50 MAUD+18.45%
-1.26 MAUD+5.21%
-1.20 MAUD-4.17%
-1.25 MAUD+37.39%
-912,965.33AUD+14.86%
-794,820.33AUD+157.82%
-308,285.33AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prescient Therapeutics Stock analysis

What does Prescient Therapeutics do? Prescient Therapeutics Ltd is an Australian biotechnology company focused on developing novel cancer therapies. The company was founded in 2006. Its business model is based on leveraging modern technologies and research findings to develop innovative solutions for cancer treatment. Prescient Therapeutics operates in two segments: drug development and research services. The company collaborates closely with leading scientists and medical institutions to utilize the latest advancements in cancer research and bring new drugs to the market. One of its products, PTX-200, is a novel inhibitor of protein kinase CK2 that has shown efficacy in clinical studies against various types of cancer. Another important product is OmniCAR, a next-generation CAR-T cell therapy that allows for selective recognition and destruction of cancer cells. Prescient Therapeutics aims to solidify its position as a leading provider of innovative cancer treatments through a rigorous validation strategy and collaboration with doctors and patients. The company has made significant progress in the development of new cancer therapies, holding numerous patents and establishing partnerships with leading medical institutions. Its goal is to meet the unmet needs of cancer patients and create a better future for cancer therapy. Prescient Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prescient Therapeutics stock

EBITDA per Employee of Prescient Therapeutics is -3.53 M AUD in 2026.

EBITDA per Employee of Prescient Therapeutics changed from -2.51 M AUD to -3.53 M AUD, representing a 40.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Prescient Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Prescient Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Prescient Therapeutics

All Key Metrics — Prescient Therapeutics